Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLH | Q9Y253 | 2/20 | 0.60 |
| ▸ | AR | P10275 | 6/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.53 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 4/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | RAF1 | P04049 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | HTR3A | P46098 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15920417 | 0.85 | POLH (0.58) | POLHARCYP3A4MAPTMEN1 | |
| SCHEMBL8121953 | 0.83 | AR (0.62) | POLHARCYP3A4MAPTMEN1 | |
| SCHEMBL2773475 | 0.83 | KDM4E (0.60) | POLHARCYP3A4MAPTMEN1 | |
| SCHEMBL24248100 | 0.83 | POLH (0.56) | POLHARCYP3A4MAPTMEN1 | |
| SCHEMBL17716251 | 0.83 | POLH (0.56) | POLHARCYP3A4MAPTMEN1 | |
| SCHEMBL16688558 | 0.82 | POLH (0.58) | POLHARCYP3A4MAPTMEN1 | |
| SCHEMBL15821014 | 0.81 | POLH (0.58) | POLHARCYP3A4MAPTMEN1 | |
| SCHEMBL21089969 | 0.81 | POLH (0.54) | POLHARCYP3A4MAPTMEN1 | |
| SCHEMBL13543171 | 0.81 | KDM4E (0.66) | MAPTMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL14752570 | 0.79 | ALOX15 (0.57) | POLHARCYP3A4MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988340-B2 | Compositions and methods for the treatment of multiple sclerosis | CELLIX BIO PRIVATE LIMITED (IN) | 2018-06-05 | — | — | US | disclosed |
| US-9988340-B2 | Compositions and methods for the treatment of multiple sclerosis | CELLIX BIO PRIVATE LIMITED (IN) | 2018-06-05 | — | — | US | disclosed |
| US-9580383-B2 | Compositions and methods for the treatment of multiple sclerosis | CELLIX BIO PRIVATE LIMITED (IN) | 2017-02-28 | — | — | US | disclosed |
| US-9580383-B2 | Compositions and methods for the treatment of multiple sclerosis | CELLIX BIO PRIVATE LIMITED (IN) | 2017-02-28 | — | — | US | disclosed |
| US-9498461-B2 | Compositions and methods for the treatment of inflammatory bowel disease | CELLIX BIO PRIVATE LIMITED (IN) | 2016-11-22 | — | — | US | disclosed |
| US-9394288-B2 | Compositions and methods for the treatment of asthma and allergy | CELLIX BIO PRIVATE LIMITED (IN) | 2016-07-19 | — | — | US | disclosed |
| US-9333187-B1 | Compositions and methods for the treatment of inflammatory bowel disease | CELLIX BIO PRIVATE LIMITED (IN) | 2016-05-10 | — | — | US | disclosed |
| US-20160122291-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | CELLIX BIO PRIVATE LIMITED (IN) | 2016-05-05 | — | — | US | disclosed |
| US-20160120839-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CELLIX BIO PRIVATE LIMITED (IN) | 2016-05-05 | — | — | US | disclosed |
| US-20160120838-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CELLIX BIO PRIVATE LIMITED (IN) | 2016-05-05 | — | — | US | disclosed |
| US-20160090350-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | CELLIX BIO PRIVATE LIMITED (IN) | 2016-03-31 | — | — | US | disclosed |
| US-9227974-B2 | Compositions and methods for the treatment of respiratory disorders | CELLEX BIO PRIVATE LIMITED (IN) | 2016-01-05 | — | — | US | disclosed |
| US-9102649-B1 | Compositions and methods for the treatment of multiple sclerosis | CELLIX BIO PRIVATE LIMITED (IN) | 2015-08-11 | — | — | US | disclosed |
| US-20150133407-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISORDERS | CELLIX BIO PRIVATE LIMITED (IN) | 2015-05-14 | — | — | US | disclosed |
| US-20150126593-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ASTHMA AND ALLERGY | CELLIX BIO PRIVATE LIMITED (IN) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160120838-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALPI, SLC10A2, SI | POLH 2936/4885AR 4084/4885CYP3A4 84/4885 |
| US-20150126593-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ASTHMA AND ALLERGY | LTA4H, LTC4S, ALOX5 | POLH 2717/4885AR 670/4885CYP3A4 35/4885 |
| US-20160122291-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | PMP22, SI, AQP4 | POLH 2421/4885AR 1962/4885CYP3A4 302/4885 |
| US-20160090350-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | PMP22, SI, AQP4 | POLH 2243/4885AR 2289/4885CYP3A4 356/4885 |
| US-20160120839-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALPI, SLC10A2, SI | POLH 2936/4885AR 4084/4885CYP3A4 84/4885 |
| US-20150133407-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISORDERS | SORD, MUC1, CFTR | POLH 3809/4885AR 849/4885CYP3A4 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.